Inactive Instrument

Highlights Willow Biosciences Inc Canadian Securities Exchange

Equities

CA97111B1076

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Willow Biosciences Provides Corporate Update and Signs New Partnered Program	27/06	MT
Willow Biosciences Brief: Announced multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients	27/06	MT
Willow Biosciences Brief: Expanding into the high growth biopesticide sector with addition of new partnered program	27/06	MT
Willow Biosciences Brief: Announces its first patent being issued; Anticipates filing another five patents in 2024 primarily related to its steroid production platform	27/06	MT
Willow Biosciences Brief: Anticipates revenue of over $1.0 million in Q2, and over $3.5 million for 2024 on existing programs	27/06	MT
Willow Biosciences Brief: Providing Corporate Update and Signs New Partnered Program	27/06	MT
Willow Biosciences Signs Multi-Product Development, Licensing Partnership With Laurus Lab	30/05	MT
Willow Biosciences Brief: Announcing Multi-product Development and Licensing Partnership With Laurus Lab	30/05	MT
Willow Biosciences Inc. Announces Multi-Product Development and Licensing Partnership with Laurus Labs	30/05	CI
Willow Biosciences Brief: Reiterating its Expectations of at least doubling its full year 2024 revenues, As Reports Q1 Results	13/05	MT
Willow Biosciences Inc. Provides Earnings Guidance for the Fiscal Year 2024	13/05	CI
Willow Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05	CI
Willow Biosciences Narrows 2023 Loss YOY	01/04	MT
Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
Willow Biosciences Announces Second Strategic Investment From Kalsec	01/03	MT
Willow Biosciences Enters Partnership With Global Ingredient Manufacturer	31/01	MT
Willow Biosciences Inc. Announces Collaboration with Global Active Pharmaceutical Ingredient Manufacturer to Develop A More Sustainable, Cost-Effective Manufacturing Process for A Large Volume Global Market	31/01	CI
Willow Biosciences Announces Collaboration with Active Pharmaceutical Ingredient Manufacturer to Manufacture More Sustainable, Cost-Effective Manufacturing Route for Their Largest Product Sold Globally	31/01	CI
Willow Biosciences Announces Collaboration With Enterin	16/01	MT
Willow Biosciences Inc. Announces Collaboration with Enterin, Inc. to Develop Sustainable Interimates and Active Pharmaceutical Ingredients	16/01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Willow Biosciences Inc Canadian Securities Exchange

Equities

CA97111B1076

Highlights

Filters